EU CR 2025/1901: definitive anti-dumping duties on glyoxylic acid from China (5-year)

Mechanism

Glyoxylic acid is a bifunctional α-keto acid (IUPAC: 2-oxoacetic acid) that serves as a critical upstream building block for multiple downstream chemical chains:

• Pharmaceuticals: precursor to vanillin (via hydroxyphenylglycine pathway), atenolol

(cardiovascular active pharmaceutical ingredient), allantoin (wound-healing/cosmetic), and various synthetic vitamin B complex precursors.

• Cosmetics: preservative chemistry intermediates and fragrance precursors.
• Food & flavourings: vanillin synthesis route.
• Fertilizers: chelating-agent component.

China holds dominant global production capacity in glyoxylic acid, led by Hubei Hongyuan and Xinjiang Guolin. The EU's producer base consists of a single, shrinking European manufacturer unable to compete with Chinese prices inflated by state subsidies and overcapacity.

The investigation was initiated on 25 July 2024 following a complaint by the EU producer. Provisional duties (up to 280.3%) were imposed under Regulation (EU) 2025/591 on 24 March 2025. The definitive measure (EU) 2025/1901 was adopted 22 September 2025 under Article 9(4) and Article 10(2) of the Basic AD Regulation (EU) 2016/1036 for a five-year duration.

Duty rate structure:

The 210.5% residual rate for non-cooperating Chinese producers is among the highest 2025-vintage EU AD rates against a single chemicals input, signaling a high-injury-finding posture by DG Trade against unfair Chinese chemicals pricing.

Downstream implications

• Directly operationalises the EU Chemicals Industry Action Plan (COM(2025) 530,

2025-07-08-eu-chemicals-industry-action-plan-com-2025-530) which explicitly named glyoxylic acid as an in-flight TDI investigation alongside PVC, melamine, ethanolamines, and polyols.

• Increases input costs for EU pharmaceutical manufacturers reliant on Chinese-sourced glyoxylic

acid; may accelerate supply-chain diversification toward non-Chinese producers or bio-based glyoxylic acid routes.

• Demonstrates EU TDI cadence against Chinese chemicals overcapacity in the context of the

EUR 305bn EU-China bilateral trade deficit (2024).

• The 210.5% blanket non-cooperating rate creates a de facto import barrier for most Chinese

spot exporters, effectively channelling remaining EU-bound volumes through the two cooperating Chinese producers (lower rates) or EU/non-CN production.

Open questions

• Whether EU pharmaceutical majors (Sanofi, Bayer, Boehringer Ingelheim) will seek product

exclusions or whether the single EU producer can ramp volume to substitute Chinese supply.

• Whether follow-on TDI investigations on vanillin or hydroxyphenylglycine (the next step

downstream) will extend the protective perimeter.

• Timing and scope of the next glyoxylic acid investigation cycle at the five-year expiry review.